This shift poses critical implications for vaccine efficacy, as current dengue vaccines have shown limited effectiveness against DENV-3 in clinical trials.
The study emphasises the importance of region-specific serotype understanding, which is essential as India moves toward phase 3 trials of quadrivalent dengue vaccines.
The authors emphasise that as India prepares for phase 3 trials of quadrivalent dengue vaccines, understanding region-specific circulating dengue virus serotypes is crucial.